Search 

Biovotion AG is a Swiss based medical device company, providing solutions for continuous, non-invasive physiological monitoring. The Biovotion Vital Sign Monitoring (VSM) platform is a mobile, standalone wearable monitor of vital sign parameters, supported by integrated cloud services for data exchange and analysis. It is directed towards patients with chronic conditions featuring Biovotion’s patient-friendly, wearable monitoring concept.

The company holds internationally recognised know how, paired with an extensive IP portfolio in a number of fields, relevant to provide sensor technology and device development for continuous and non-invasive physiological monitoring, embedded into mHealth environments.

eADMET is an expert in the creation of customised computational models for the prediction of ADME/Tox properties of small drug-like molecules. eADMET’s modular approach combines proprietary and selected external algorithms to create customised prediction models (with integrated error estimation) for clients and partners from the pharmaceutical and biotechnology industry.

eADMET’s product portfolio includes:

1. OCHEM - a public accessible reference system and database
2. Validated models for precise prediction of various ADME/Tox parameters
3. User-friendly customized model solutions for specific customer needs
4. Expert consultancy services with respect to model application and interpretations.

New developments include chemogenomic methods and methods for in vitro to in vivo correlations to address toxicity prediction within drug discovery and REACH.

eADMET was founded as a result of GO-Bio project awarded to Dr Tetko with a financial support from High-Tech Gründerfonds (HTGF) and Bayern Kapital. it is a spinout from Helmholtz Centre, Munich.

Northern Biotechnologies has raised $1.5M in round "a" private funding. Northern is seeking commercialization and investment partnerships to continue the development of additional anti-bacterial, anti- viral and anti-fungal applications of our technology which require additional testing, proof of concept and commercialization partners.

Northern Biotechnologies is pioneering the commercialization of an innovative, long lasting, therapeutic anti-microbial technology that has significant applications in the Human Health Care arena. Infectious disease control and prevention

can be revolutionized by integration of our cost saving technology. Issued Patents and proprietary production IP offer a stable platform for growth and partnership into all human related applications of the technology. A unique feature of the technology is its extended protection of 1-3 days through each application. Additionally, the physical method of pathogen destruction prevents formation of resistant strain types, in contrast to existing technologies that rely on metabolic action for kill. Testing shows high performance anti-bacterial, anti-fungal and anti- viral functioning in various direct, topical, and wound care, nasal/ oral and related dosing mechanisms of the technology. We are in process with the first New Drug Application for antiseptic hand wash, and are looking for partners to pursue additional drug approvals in specific markets.

Existing product branding in the Human market is Prefense hand sanitizer and wipes. In addition to human applications, Northern holds over twenty-five global patents for anti-microbial water filtration using our technology. We also hold EPA registrations for persistent antimicrobial filter media. Significant opportunity exists in the technology used as a multi surface sanitizer for all levels of food production. Other existing product lines and cash flow are in place from additional internally developed technologies including high performance filtration medias, biotech remediation and process technologies used in petroleum, agricultural, and industrial processing. Northern also holds nationally placed consumer and professional brand lines of "green probiotic" cleaning products based on our IP and manufacturing base. Additionally, our cGMP contract packaging division sells our proprietary formulations to many national brands in a variety of markets. Company management is made of a diverse team with the experience and drive required to steer strong growth and relationships with partner companies. 

The PROTAGEN GROUP is a leading provider of solutions for the

Pharmaceutical and Biotech industries, supporting drug development towards

personalized medicines and GMP compliant protein characterization services

of outstanding quality.

The PROTAGEN GROUP consists of PROTAGEN AG with a clear focus on

diagnostics, and PROTAGEN Protein Services GmbH (PPS) providing GMP

compliant protein analysis.

PROTAGEN AG has developed the proprietary UNIarray® platform to support

patient stratification and the development of Companion Diagnostics (CDx)

using the diagnostic power of autoantibody signatures in blood. We combine

our outstanding know-how in biostatistics and expertise in Protein arrays and

Luminex technology for the development of novel diagnostic assays. Our R&D

focus is on chronic diseases, e.g. neurodegenerative disorders, endometriosis,

autoimmune diseases such as Rheumatoid Arthritis, Systemic Lupus

Erythematosus and Multiple Sclerosis as well as selected cancer indications,

e.g. Prostate-, Breast-, Ovarian-, Colon- and Pancreatic Cancer.

PROTAGEN Protein Services GmbH (PPS)

is a reliable partner for GMP compliant characterization of biotherapeutics

(NBEs) and biosimilar comparability, including stability and release testing.

PPS combines unique expertise in bioinformatics for protein mass spectrometry

with a long track record in protein chemistry and protein analytics in order to

provide the best quality available. In addition, we provide customer support for

all relevant regulatory issues to match with current regulatory requirements

(FDA, EMA, KFDA) for protein drugs.

Selcia Ltd., headquartered in Ongar, Essex, UK and with a branch in Hopkinton, Massachusetts, is a leading worldwide provider of contract research services. Selcia operates two divisions, Selcia Discovery and Selcia Radiochemistry. Whilst Radiochemistry specializes in 14C GMP radiolabelling, Selcia Discovery provides integrated small molecule drug discovery to pharmaceutical and biotech clients. Besides general medicinal chemistry and biology capabilities applicable across all target classes, Selcia Discovery has a particular strength in three unique and highly synergistic technologies: (1) medicinal chemistry on complex natural products, (2) capillary electrophoresis-based fragment and natural product screening, (3) peptidyl-prolyl isomerase targets (cyclophilins, FKBPs, Pin1, together called PPIases). Whilst relatively neglected by pharmaceutical companies in the past, understanding of the involvement of PPIases in many diseases is currently emerging. All PPIase inhibitors presently in clinical use or in development are natural products, natural product derivatives or have structures inspired by natural products.

The combination of these technologies has enabled Selcia to deliver several clinical PPIase inhibitors to clients, but has also generated IP for Selcia, which was recently demerged into a new company, Mitopharm Ltd. Mitopharm is in advanced license negotiations for a breakthrough drug in the field of acute and chronic neurodegenerative diseases. Other applications in the fields of chronic inflammatory diseases, oncology, COPD, and virus infections will be developed by Mitopharm either via investment or via joint R&D programs with pharmaceutical companies.